A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC)

Luis E. Raez*, Edgardo S. Santos, R. Timothy Webb, James Wade, Roger A. Brito, Melissa Karr, Andra Kennah, Barrett H. Childs

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Fingerprint

Dive into the research topics of 'A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC)'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds